tbuckley/cabot-search huggingface dataset:
Abstract 15536: Chest Compressions During Sustained Inflations: A Novel Technique of Neonatal Resuscitation That Improves Recovery and Survival in a Neonatal Porcine Model
Authors: Georg Schmolzer, Megan O’Reilly, Joseph LaBossiere, Tze-Fun Lee, Shaun Cowan, David Bigam, Po-Yin Cheung
Journal: Circulation (2013)

Background: Guidelines on neonatal resuscitation recommend 90 chest compressions (CC) and 30 manual inflations (3:1) per minute in newborn infants. However, the optimal compressions to inflations ratio remains unknown. Objective: The study aimed to determine if CCs during sustained inflations (SI) improves return of spontaneous circulation (ROSC) of asphyxiated newborn piglets compared to coordinated 3:1 resuscitation. Methods and Results: Term newborn piglets (n=8/group) were anesthetized, intubated, instrumented and exposed to 45-minute normocapnic hypoxia followed by asphyxia. Protocolized resuscitation was initiated when heart rate decreased to 25% of baseline. Piglets were randomized to receive either 3:1 resuscitation (3:1 group) according to the current resuscitation guidelines, or CCs during SIs (SI group). Piglets randomized to the SI group received a SI with a peak inflating pressure of 30 cm H2O for 30 sec. During the SI, CCs were provided at a rate of 120 per minute. SI was interrupted after 3...
Proteomic Analysis of Histones H2A/H2B and Variant Hv1 in Tetrahymena thermophila Reveals an Ancient Network of Chaperones
Authors: Kanwal Ashraf, Syed Nabeel-Shah, Jyoti Garg, Alejandro Saettone, Joanna Derynck, Anne-Claude Gingras, Jean-Philippe Lambert, Ronald E Pearlman, Jeffrey Fillingham
Journal: Molecular Biology and Evolution (2019)

Epigenetic information, which can be passed on independently of the DNA sequence, is stored in part in the form of histone posttranslational modifications and specific histone variants. Although complexes necessary for deposition have been identified for canonical and variant histones, information regarding the chromatin assembly pathways outside of the Opisthokonts remains limited. Tetrahymena thermophila, a ciliated protozoan, is particularly suitable to study and unravel the chromatin regulatory layers due to its unique physical separation of chromatin states in the form of two distinct nuclei present within the same cell. Using a functional proteomics pipeline, we carried out affinity purification followed by mass spectrometry of endogenously tagged T. thermophila histones H2A, H2B and variant Hv1.We identified a set of interacting proteins shared among the three analyzed histones that includes the FACT-complex, as well as H2A- or Hv1-specific chaperones. We find that putative subunits of T. thermophila versions of SWR- and INO80-complexes, as well as transcription-related histone chaperone Spt6Tt specifically copurify with Hv1. We also identified importin β6 and the T. thermophila ortholog of nucleoplasmin 1 (cNpl1Tt) as H2A–H2B interacting partners. Our results further implicate Poly [ADP-ribose] polymerases in histone metabolism. Molecular evolutionary analysis, reciprocal affinity purification coupled to mass spectrometry experiments, and indirect immunofluorescence studies using endogenously tagged Spt16Tt (FACT-complex subunit), cNpl1Tt, and PARP6Tt underscore the validity of our approach and offer mechanistic insights. Our results reveal a highly conserved regulatory network for H2A (Hv1)–H2B concerning their nuclear import and assembly into chromatin.
Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive Behavioral Therapy vs Supportive Psychotherapy for Adults With Body Dysmorphic Disorder
Authors: Sabine Wilhelm, Katharine A. Phillips, Jennifer L. Greenberg, Sheila M. O’Keefe, Susanne S. Hoeppner, Aparna Keshaviah, Suraj Sarvode-Mothi, David A. Schoenfeld
Journal: JAMA Psychiatry (2019)

Cognitive behavioral therapy (CBT), the best-studied treatment for body dysmorphic disorder (BDD), has to date not been compared with therapist-delivered supportive psychotherapy, the most commonly received psychosocial treatment for BDD. To determine whether CBT for BDD (CBT-BDD) is superior to supportive psychotherapy in reducing BDD symptom severity and associated BDD-related insight, depressive symptoms, functional impairment, and quality of life, and whether these effects are durable. This randomized clinical trial conducted at Massachusetts General Hospital and Rhode Island Hospital recruited adults with BDD between October 24, 2011, and July 7, 2016. Participants (n = 120) were randomized to the CBT-BDD arm (n = 61) or the supportive psychotherapy arm (n = 59). Weekly treatments were administered at either hospital for 24 weeks, followed by 3- and 6-month follow-up assessments. Measures were administered by blinded independent raters. Intention-to-treat statistical analyses were performed from February 9, 2017, to September 22, 2018. Cognitive behavioral therapy for BDD, a modular skills-based treatment, addresses the unique symptoms of the disorder. Supportive psychotherapy is a nondirective therapy that emphasizes the therapeutic relationship and self-esteem; supportive psychotherapy was enhanced with BDD-specific psychoeducation and treatment rationale. The primary outcome was BDD symptom severity measured by the change in score on the Yale-Brown Obsessive-Compulsive Scale Modified for BDD from baseline to end of treatment. Secondary outcomes were the associated symptoms and these were assessed using the Brown Assessment of Beliefs Scale, Beck Depression Inventory-Second Edition, Sheehan Disability Scale, and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. Of the 120 participants, 92 (76.7%) were women, with a mean (SD) age of 34.0 (13.1) years. The difference in effectiveness between CBT-BDD and supportive psychotherapy was site specific: at 1 site, no difference was detected (estimated mean [SE] slopes, -18.6 [1.9] vs -16.7 [1.9]; P = .48; d growth-modeling analysis change, -0.25), whereas at the other site, CBT-BDD led to greater reductions in BDD symptom severity, compared with supportive psychotherapy (estimated mean [SE] slopes, -18.6 [2.2] vs -7.6 [2.0]; P < .001; d growth-modeling analysis change, -1.36). No posttreatment symptom changes were observed throughout the 6 -months of follow-up (all slope P ≥ .10). Body dysmorphic disorder severity and associated symptoms appeared to improve with both CBT-BDD and supportive psychotherapy, although CBT-BDD was associated with more consistent improvement in symptom severity and quality of life. ClinicalTrials.gov identifier: NCT01453439.
IMMU-39. COMBINATION OF RADIOTHERAPY WITH A 4-1BB AGONIST ANTIBODY AND A TIM-3 APTAMER RESULTS IN ENHANCED SURVIVAL IN A DIPG MODEL
Authors: Naiara Martínez-Vélez, Miguel Marigil Sanchez, Monsterrat Puigdelloses, Marc Garcia-Moure, Jose Javier Aristu, Pablo Dominguez, Mikel Rico, Oren Becher, Luis Ramos, Fernando Pastor, Ricardo Diez Valle, Sonia Tejada, Marta M Alonso
Journal: Neuro-Oncology (2017)

Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric tumors. Despite advances in targeted treatments radiotherapy remains as the standard treatment being just palliative. The lack of effective therapies represents a critical unmet need for many pediatric solid tumors. Cancer immunotherapy is an ideal alternative choice since the immune response is highly specific; it would persist along time creating memory and will get rid of infiltrative cells even if they are far away. 4-1BB is a major costimulatory receptor promoting the survival and expansion of activated T cells. Aptamers are high-affinity single-stranded nucleic acid ligands that exhibit remarkable affinity and specificity to their targets, comparable or exceeding that of antibodies. TIM-3 is a negative regulator of lymphocyte function that is involved in T-cell exhaustion. In this work we examined the anti-tumor effect of radiotherapy in combination with an agonist 4-1BB antibody and an aptamer against TIM-3. Of importance neither of the treatments resulted in fatal toxicities. Moreover, Combination treatment of 4-1BB with radiotherapy resulted in a significant improvement in survival in mice bearing DIPG orthotopic tumors when compared with single treatment. In addition, this combination led to long-term survivors (90 days). Currently we are performing rechallenge experiments in these animals. Further combination of radiotherapy, with the 4-1BB antibody and the TIM-3 aptamer, that released the immune suppression, is currently under study. At this point the combination between the three approaches showed lack of toxicity. Survival studies are on-going. Mechanistic studies performed on day 16 showed an increase in CD8 effector cells, a decrease in T-regulators Foxp3+ cells and an increase in INF-gamma expression suggesting the triggering of an antitumor-immune response. These results suggest that immuno-therapies approaches in combination with radiotherapy would be worth to explore in the treatment of deadly DIPGs.
Association of Atherosclerosis Prevalence With Age, Race, and Traditional Risk Factors in Patients With Psoriasis
Authors: Kathryn A. Arnold, Alison D. Treister, Peter A. Lio, Francis J. Alenghat
Journal: JAMA Dermatology (2019)

Association of Atherosclerosis Prevalence With Age, Race, and Traditional Risk Factors in Patients With PsoriasisPsoriasis is a chronic skin condition associated with systemic inflammation. 1This inflammation may promote atherosclerosis, and multiple studies have shown an association between psoriasis and atherosclerotic cardiovascular disease (ASCVD). 2 Although this association scales with severity and duration of skin disease, 3,4 little is known about race-and age-specific factors.Furthermore, the association between psoriasis and atherosclerosis in the absence of traditional cardiovascular risk factors is controversial. 5Our dual-center study aims to elucidate whether certain characteristics of patients with psoriasis are disproportionally associated with ASCVD.
Evaluating Digital Health Tools—Prospective, Experimental, and Real World
Authors: Andrew D. Auerbach
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Immunophenotypic and Genetic Characteristics of Diffuse Large B-Cell Lymphoma (DLBCL), and Prognostic Significance of Cell of Origin (COO) in a Southeast Asian Cohort
Authors: Vanessa CL Chong, Eng Soo Yap, Liu Xin, Suk Teng Chin, Anand Jeyasekharan, Yen-Lin Chee, Hian Li Esther Chan, Sanjay De Mel, Joanne Shu Xian Lee, Yee Mei Lee, Yi Ching Yuen, Liang Piu Koh, Michelle Poon
Journal: Blood (2018)
Abstract 17115: Hyperinsulinemia/Insulin-Resistance Causes Left Ventricular Remodeling in Patients With a First STEMI Despite the Smaller Infarction: 3D Speckle Tracking Study
Authors: Noriaki Iwahashi, Hironori Takahashi, Yuichiro Kimura, Yasushi Matsuzawa, Masaaki Konishi, Nobuhiko Maejima, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Kazuo Kimura, Kouichi Tamura
Journal: Circulation (2017)

Background: Insulin resistance(IR) and hyperinsulinemia(HI) have been reported to be associated with prognosis in patients with heart disease and poor prognosis. Methods: 172 patients with a first-...
Catalogue of failings at Lancashire hospital led to woman’s death after hip surgery, finds ombudsman
Authors: Clare Dyer
Journal: BMJ (2019)

A woman died after routine hip replacement surgery because of a catalogue of errors by the NHS trust that was caring for her, the Parliamentary and Health Service Ombudsman has concluded.1

Renie Craig, 77, would have survived the low risk operation had East Lancashire Hospitals NHS Trust properly monitored and treated her after the surgery, the ombudsman found.

Her son, Ian Craig, complained to the ombudsman, arguing that the trust’s own investigation was inadequate.

Craig was scheduled to have the operation in February 2015. She had high blood pressure and several tests from December 2014 showed that …
Treasurer's Report for Financial Year (FY) 2011
Authors: A. McLysaght
Journal: Molecular Biology and Evolution (2013)

The society’s total assets as of May 31, 2012, are as follows: 


Cash accounts (community checking + money market business): $776,190.96


Total CDs: $183,202.71






This report covers the period from June 1, 2011, to May 31, 2012. Because of the ongoing success of Molecular Biology and Evolution (MBE), whose revenue continues to increase, the society remains in outstanding financial health. Society membership decreased during FY 2011: Membership-only subscriptions decreased from 541 in 2010 to 456 in 2011, whereas society membership + journal subscriptions decreased from 334 in 2010 to 239 in 2011.


The society used its income to publish its two journals, MBE and Genome Biology and Evolution (GBE), to support a satellite meeting on Phylomedicine in Arizona, USA, and to support its annual meeting in 2012, held in Dublin, Ireland. This included providing graduate and postdoctoral travel awards, funding the Walter Fitch Prize Symposium (a cash prize for the winner and travel funds for eight contestants), running the Undergraduate Diversity Mentoring Program, supporting the travel/accommodation of Council members, and providing travel incentives for associate editors of MBE and GBE. 


	Expense Category	June 1, 2011– May 31, 2012
Interest income	1,211.38	
OUP journal revenue (MBE)	549,476.00	
OUP journal revenue (GBE)	63,177.00	
Society fees collected by OUP	11,460.00	
Annual meeting reimbursement	157,893.14	
Total inflows	$782,387.52	
2012 and 2013 meetings	187,000.00	
Bank charges	225.37	
Accounting	1,700.00	
Corporation fee	40.00	
Fitch prize	1,500.00	
SMBE council and editors-in-chief travel	31,482.40	
MBE/GBE associate editors travel incentive	38,559.14	
Student awards (Fitch, undergrad, grad, and postdoc)	87,872.09	
SMBE website maintenance	3,343.80	
SMBE treasurer expenses	0.00	
MBE editorial office expenses	85,161.00	
MBE editor expenses	70,000.00	
GBE editor expenses	0.00	
GBE “Highlight” honoraria	9,767.50	
Postage	523.74	
Total outflows	$517,175.04	
Overall total	$266,042.48	


View it in a separate window
The effect of polysaccharide peptide (PSP) and paclitaxel (Taxol) on human breast solid tumor tissue in vitro
Authors: Eric Lik Hang Lui, Louis Wing Cheung Chow, Wings Tjing Yung Loo
Journal: Cancer Research (2005)

1735  INTRODUCTION - Polysaccharide peptide (PSP) is a substance isolated from the deep-layer cultivated mycelia of Coriolus versicolor Yunzhi. It stimulates both humoral and cellular immune responses, and is also a valuable adjunct in raising the white blood cell counts of patients treated with chemotherapeutic drugs. In in vitro experiments, PSP has been revealed that it may have the ability to inhibit the proliferation of leukemia, lymphoma, stomach and lung cell lines. Paclitaxel (Taxol), another plant product, which is extracted from Taxus brevifolia, is an anti-neoplastic drug. It has shown to be a promising agent for the chemotherapy of ovarian, breast, and various cancers. In this study, the effects of PSP and Taxol upon the metabolic rate and apoptosis on breast cancer tissues were observed. MATERIALS AND METHOD - 39 patients’ tissues were treated with 4, 2 and 1 mg/mL of PSP and 4.27 ug/mL of Taxol for 24 hours. ATP Bioluminescence was used to measure the metabolic rate of the tissues. SPSS was to evaluate the results. SUMMARY - All results of PSP and Taxol compared with the control group had significant effects upon the suppression of tumor activity. In 4.27 μg/mL Taxol, 81.82% of the treated samples showed a percentage decrease in metabolic rate greater than 50% when compared to the control. For the same kind of calculation, 4 mg/mL of PSP is 48.72%, 2 mg/mL of PSP is 51.28% and 1 mg/mL of PSP is 46.15%. The comparison between the used drugs and tumor grading is detailed in table 1. PSP showed a higher percentage upon low-grade tumors. Our study has proven that PSP has a direct anti-tumor effect reflected by the amount of ATP measured. After the treatment of the two chemicals, tissues of both groups showed DNA fragmentation. CONCLUSION - PSP has similar effect in vitro on decreasing the activity, reflected by measuring the amount of ATP and apoptosis, of breast carcinoma solid tumor tissue compared to Taxol. PSP has a potent to be an orally neoadjuvant agent.
Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation
Authors: Talha Badar, Narendranath Epperla, Aniko Szabo, Steven Borson, John Vaughn, Gemlyn George, Nirav N Shah, Amanda F Cashen, Mehdi Hamadani, Timothy S. Fenske
Journal: Blood (2018)
Are Rule Changes the Low-Hanging Fruit for Concussion Prevention in Youth Sport?
Authors: Carolyn A. Emery, Amanda M. Black
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
ASH 2009 meeting report—Top 10 clinically oriented abstracts in myeloproliferative neoplasms
Authors: Ayalew Tefferi
Journal: American Journal of Hematology (2009)

The 2009 American Society of Hematology annual meeting took place December 5-8, in New Orleans, Louisiana, USA.Official sources indicate over 20,000 people attended the meeting and more than 4,000 scientific abstracts were presented.Among the latter, close to 100 were in the category of BCR-ABL1-negative myeloproliferative neoplasms (MPN), including polycythemia vera, essential thrombocythemia and primary myelofibrosis.Here, I summarize and discuss the top 10 MPN abstracts, which I believe contain information that is immediately relevant to clinical practice.All 10 abstracts are published in full in the November 20, 2009 issue of Blood (volume 114, No. 22) and are identified here by their abstract numbers.
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension
Authors: Keith C. Ferdinand, Joseph L. Izzo, Jisoo Lee, Leslie Meng, Jyothis George, Afshin Salsali, Leo Seman
Journal: Circulation (2019)

Empagliflozin, a sodium-glucose cotransporter 2 inhibitor indicated for type 2 diabetes mellitus (T2DM), can lower blood pressure (BP) and reduce cardiovascular mortality in patients with T2DM and preexisting cardiovascular disease. Its effects in blacks have been understudied.In this 24-week study, 150 blacks with T2DM and hypertension had glycohemoglobin (primary end point), office and 24-hour ambulatory BP, body weight, and safety assessments. After a 2-week, open-label, placebo run-in, patients were randomly assigned to once daily empagliflozin (10 mg for the first 4 weeks, then force-titrated to 25 mg until week 24) or placebo. A mixed-effects model for repeated measures was performed on the primary and 2 key secondary end points, and an analysis of covariance for nonrepeated measures with last observation carried forward was performed for 2 other key secondary end points. Hierarchical testing was applied for these end points.Overall, 52.7% of participants were men, mean (SD) age, 56.8 (9.3) years; mean duration of T2DM, 9.3 (7.1) years. The baseline values of key parameters (mean [SD]) were as follows: glycohemoglobin, 8.59 (1.02)%; ambulatory systolic BP, 146.3 (11.0) mm Hg; and ambulatory diastolic BP, 89.4 (8.1) mm Hg. By week 24, the mean (standard error) change in glycohemoglobin in the empagliflozin group was -0.77 (0.15%) in comparison with an increase of 0.07 (0.16%) in the placebo group; placebo-corrected difference, -0.78% (95% CI, -1.18 to -0.38; P=0.0002). Reductions in body weight by week 24 were -2.38 (0.38) empagliflozin and -0.80 (0.47) placebo; the placebo-corrected difference was -1.23 kg (95% CI, -2.39 to -0.07; P=0.0382). Empagliflozin significantly reduced 24-hour ambulatory systolic BP versus placebo by weeks 12 and 24 (placebo-corrected difference, -5.21 mm Hg [95% CI, -9.24 to -1.18; P=0.0117] and -8.39 mm Hg [95% CI, -13.74 to -3.04; P=0.0025], respectively). Diastolic BP was also reduced.In blacks with T2DM, empagliflozin reduced glycohemoglobin, body weight, and BP. The effect of empagliflozin on BP increased from 12 to 24 weeks, suggesting a full antihypertensive effect takes ≥6 months to be fully realized. At week 24, the placebo-subtracted BP effect was similar to standard antihypertensive monotherapies, suggesting that empagliflozin may be beneficial for this high-risk population.URL: https://www.clinicaltrials.gov . Unique identifier: NCT02182830.